Last reviewed · How we verify
Antiplatelet-only strategy
An antiplatelet-only strategy inhibits platelet aggregation to prevent thrombotic events without additional anticoagulation.
An antiplatelet-only strategy inhibits platelet aggregation to prevent thrombotic events without additional anticoagulation. Used for Acute coronary syndrome or post-percutaneous coronary intervention management (Phase 3 trial context).
At a glance
| Generic name | Antiplatelet-only strategy |
|---|---|
| Sponsor | Icahn School of Medicine at Mount Sinai |
| Drug class | Antiplatelet agent |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
This approach uses antiplatelet agents (such as aspirin, P2Y12 inhibitors, or other platelet aggregation inhibitors) as monotherapy to reduce the risk of blood clots and cardiovascular events. Unlike dual antiplatelet therapy (DAPT) or antiplatelet plus anticoagulation combinations, this strategy relies solely on platelet inhibition, potentially reducing bleeding risk while maintaining antithrombotic efficacy in select patient populations.
Approved indications
- Acute coronary syndrome or post-percutaneous coronary intervention management (Phase 3 trial context)
Common side effects
- Bleeding
- Gastrointestinal hemorrhage
- Intracranial hemorrhage
Key clinical trials
- OPTIA-AF Trial: Rhythm-Guided Antithrombotic Strategy After AF Ablation (PHASE4)
- Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone (PHASE3)
- STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication for Oral Anticoagulant (PHASE4)
- Testing a New Treatment Strategy to Improve Secondary Stroke Prevention for Older Adults: The STROKE75+ Trial (PHASE3)
- DAPT Strategy in HBR Patients Undergoing Complex PCI Following ACS: Second-Phase Beta Testing of a Patients Decision Aid (NA)
- STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT (NA)
- Evaluation of Acute Endovascular Treatment in Symptomatic Isolated Cervical Internal Carotid Artery Occlusion (ETICA) (NA)
- Early Aggressive Strategy for Treatment of Lipid-Lowering in Acute Ischemic Stroke Delivered With Endovascular Therapy for Large Artery Occlusion (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |